EA202090397A1 - Фторопиперидиновые соединения в качестве чистых антагонистов 5-ht-рецептора - Google Patents

Фторопиперидиновые соединения в качестве чистых антагонистов 5-ht-рецептора

Info

Publication number
EA202090397A1
EA202090397A1 EA202090397A EA202090397A EA202090397A1 EA 202090397 A1 EA202090397 A1 EA 202090397A1 EA 202090397 A EA202090397 A EA 202090397A EA 202090397 A EA202090397 A EA 202090397A EA 202090397 A1 EA202090397 A1 EA 202090397A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pure
receptor antagonists
fluoropiperidine
compounds
fluoropiperidine compounds
Prior art date
Application number
EA202090397A
Other languages
English (en)
Inventor
Рамакришна Нироджи
Анил Карбхари Схинде
Абдул Рашид Мохаммед
Раджеш Кумар Бадандже
Кумар Боджджа
Винод Кумар Гоял
Сантош Кумар Пандей
Джагадиш Бабу Тхенту
Венкатесварлу Джасти
Original Assignee
Сувен Лайф Сайенсиз Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сувен Лайф Сайенсиз Лимитед filed Critical Сувен Лайф Сайенсиз Лимитед
Publication of EA202090397A1 publication Critical patent/EA202090397A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к фторпиперидиновым соединениям формулы (I), их стереоизомерам, изотопным формам или их фармацевтически приемлемым солям в качестве антагонистов рецептора 5-HT. В частности, настоящее изобретение раскрывает способы получения, фармацевтическую композицию, комбинации и применение фторпиперидиновых соединений, их стереоизомеров, изотопных форм или их фармацевтически приемлемых солей.
EA202090397A 2017-08-07 2018-08-06 Фторопиперидиновые соединения в качестве чистых антагонистов 5-ht-рецептора EA202090397A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201741028024 2017-08-07
PCT/IB2018/055894 WO2019030641A1 (en) 2017-08-07 2018-08-06 FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT 6 RECEPTOR ANAGONISTS

Publications (1)

Publication Number Publication Date
EA202090397A1 true EA202090397A1 (ru) 2020-05-25

Family

ID=63678636

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090397A EA202090397A1 (ru) 2017-08-07 2018-08-06 Фторопиперидиновые соединения в качестве чистых антагонистов 5-ht-рецептора

Country Status (26)

Country Link
US (1) US10973831B2 (ru)
EP (1) EP3649124B1 (ru)
JP (1) JP6808088B2 (ru)
KR (1) KR102190332B1 (ru)
CN (1) CN111051302B (ru)
AU (1) AU2018313049B2 (ru)
BR (1) BR112020002227A2 (ru)
CA (1) CA3071084C (ru)
CY (1) CY1124174T1 (ru)
DK (1) DK3649124T3 (ru)
EA (1) EA202090397A1 (ru)
ES (1) ES2874628T3 (ru)
HR (1) HRP20210822T1 (ru)
HU (1) HUE055186T2 (ru)
IL (1) IL272287B (ru)
LT (1) LT3649124T (ru)
MA (1) MA50036B1 (ru)
MD (1) MD3649124T2 (ru)
MX (1) MX2020001311A (ru)
PL (1) PL3649124T3 (ru)
PT (1) PT3649124T (ru)
RS (1) RS61886B1 (ru)
SG (1) SG11202000833YA (ru)
SI (1) SI3649124T1 (ru)
WO (1) WO2019030641A1 (ru)
ZA (1) ZA202000758B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021014271A (es) * 2019-05-24 2022-01-06 Integrative Res Laboratories Sweden Ab Sales farmaceuticamente aceptables de [2-(3-fluoro-5-metanosulfoni lfenoxi)etil](propil)amina y usos de las mismas.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100390157C (zh) 2002-11-08 2008-05-28 弗·哈夫曼-拉罗切有限公司 取代的苯并嗪酮及其用途
US7378415B2 (en) * 2004-09-30 2008-05-27 Roche Palo Alto Llc Benzoxazine and quinoxaline derivatives and uses thereof
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders

Also Published As

Publication number Publication date
IL272287B (en) 2021-07-29
US20200155560A1 (en) 2020-05-21
CN111051302A (zh) 2020-04-21
CA3071084A1 (en) 2019-02-14
IL272287A (en) 2020-03-31
MA50036A (fr) 2020-05-13
EP3649124B1 (en) 2021-03-03
SI3649124T1 (sl) 2021-09-30
BR112020002227A2 (pt) 2020-07-28
MX2020001311A (es) 2020-03-20
EP3649124A1 (en) 2020-05-13
KR20200022517A (ko) 2020-03-03
DK3649124T3 (da) 2021-05-31
JP6808088B2 (ja) 2021-01-06
CY1124174T1 (el) 2022-05-27
ZA202000758B (en) 2021-03-31
KR102190332B1 (ko) 2020-12-11
NZ762057A (en) 2022-03-25
MA50036B1 (fr) 2021-06-30
PL3649124T3 (pl) 2021-08-16
CA3071084C (en) 2021-01-19
SG11202000833YA (en) 2020-02-27
LT3649124T (lt) 2021-06-10
JP2020526573A (ja) 2020-08-31
HRP20210822T1 (hr) 2021-08-20
RS61886B1 (sr) 2021-06-30
ES2874628T3 (es) 2021-11-05
AU2018313049A1 (en) 2020-02-20
WO2019030641A1 (en) 2019-02-14
AU2018313049A8 (en) 2020-02-27
PT3649124T (pt) 2021-06-01
HUE055186T2 (hu) 2021-11-29
US10973831B2 (en) 2021-04-13
MD3649124T2 (ro) 2021-07-31
CN111051302B (zh) 2021-04-09
AU2018313049B2 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
MX2018011831A (es) Antagonistas solubles de receptor de c5aa(c5ar).
MX2019002180A (es) Moduladores alostericos positivos del receptor m1 muscarinico.
EA201691302A1 (ru) Новые гетероциклические соединения
EA201591195A1 (ru) Новые хинолоновые производные
EA202091262A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
EA201690888A1 (ru) Новые гетероциклические соединения
EA201791829A1 (ru) Амидные соединения в качестве агонистов рецептора 5-ht
EA201590364A1 (ru) Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
EA201501163A1 (ru) Модуляторы рецептора cxcr7
EA201691920A1 (ru) Новые конденсированные соединения имидазобензотиазола
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
EA201691252A1 (ru) Соединения индазола в качестве агонистов 5-ht-рецептора
EA201892529A1 (ru) Комбинация чистых антагонистов 5-htрецепторов с ингибиторами ацетилхолинэстеразы
EA202090995A1 (ru) Полициклические амиды в качестве положительных аллостерических модуляторов мускариновых рецепторов м1
EA201892583A1 (ru) Комбинация чистых антагонистов 5-htрецептора с антагонистом nmda рецептора
EA201892528A1 (ru) Трехкомпонентная комбинация чистых антагонистов 5-htрецепторов, ингибиторов ацетилхолинэстеразы и антагониста nmda рецептора
EA202090397A1 (ru) Фторопиперидиновые соединения в качестве чистых антагонистов 5-ht-рецептора
NZ764004A (en) Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators
EA201991045A1 (ru) Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора
PH12017501736A1 (en) Indole derivatives
EA202191046A1 (ru) Производные пирролопиридазина, как позитивные аллостерические модуляторы мускаринового рецептора m1
NZ764561A (en) Substituted azacycles as muscarinic m1 receptor positive allosteric modulators